A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy

  • Cancer
  • Non-Hodgkin's Lymphoma
  • Diffuse Large B-Cell Lymphoma
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Ann Arbor
  • Baltimore
  • Barcelona
  • Be'er Sheva
  • Birmingham
  • Busan
  • Chicago
  • Cáceres
  • Daegu
  • Dallas
  • Durham
  • Fort Wayne
  • Gdańsk
  • Gdynia
  • Haifa
  • Incheon
  • Jerusalem
  • Kefar Sava
  • Kraków
  • L'Hospitalet de Llobregat
  • Louisville
  • Lublin
  • Madrid
  • Miami
  • Netanya
  • New Taipei City
  • New York
  • Opole
  • Petah Tikva
  • Philadelphia
  • Portland
  • Providence
  • Ramat Gan
  • Rehovot
  • Santa Monica
  • Seoul
  • Sevilla
  • Tainan City
  • Taipei City
  • Tampa
  • Tel Aviv-Yafo
  • València
  • Warszawa
Trial Identifier:

NCT03677154 GO40554

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.

      Hoffmann-La Roche Sponsor
      Phase 1/Phase 2 Phase
      NCT03677154,GO40554 Trial Identifier
      Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin, Tocilizumab Treatments
      Diffuse Large B-cell Lymphoma Condition
      Official Title

      A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria

      Inclusion Criteria for All Cohorts

      • At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest diameter
      • Adequate hematologic function
      • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2; with the exception of South Korea, where participants 80 years or older with ECOG >/= 2 will not be eligible

      Inclusion Criteria Specific to Cohort A

      Participants in Cohort A must also meet the following criteria for study entry:

      • Histologically confirmed DLBCL according to World Health Organization (WHO) 2016 expected to express the cluster of differentiation-20 (CD20) antigen
      • One prior therapy with any systemic anthracycline-based chemoimmunotherapy containing regimen for previously untreated DLBCL
      • Best response of SD or PR to prior systemic chemoimmunotherapy at the end of induction treatment in accordance with the Lugano 2014 criteria

      Inclusion Criteria Specific to Cohorts B and C

      Participants in Cohorts B and C must also meet the following criteria for study entry:

      • Previously untreated, histologically confirmed, DLBCL according to WHO 2016 classification
      • Age >/= 80 years, or
      • Age 65-79 years and considered ineligible for chemoimmuotherapy (R-CHOP) with at least one of the following: Impairment in at least two activity of daily living (ADL) components as defined in the protocol; impairment in at least two instrumental ADL components as defined in the protocol; cumulative illness rating scale - geriactic (CIRS-G) score of at least one cormorbidity with a severity score of 3-4 (not including lymphoma and hematologic deficiencies due to lymphoma) or a score of 2 in >/= 8 comorbidities; impairment in cardiac function, renal function, liver function, or other comorbidities such that the participant is unfit for full-dose immunochemotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
      • Participants with an initial ECOG performance status of 3 may be considered during screening if the performance status is DLBCL-related and if pre-phase treatment during the screening phase (not more than 100 mg/day up to 7 days prior to Cycle 1 Day 1) results in an improvement of ECOG performance status to </= 2 prior to enrollment
      Exclusion Criteria

      Exclusion Criteria for All Cohorts

      Participants who meet any of the following criteria will be excluded from study entry:

      • Transformed lymphoma
      • CNS lymphoma
      • Prior treatment with mosunetuzumab
      • Prior stem cell transplant (autologous and allogeneic)
      • History of confirmed progressive multifocal leukoencephalopathy (PML)
      • Known or suspected chronic active Epstein Barr virus (CAEBV), hepatitis B, hepatitis C (HCV), or Human Immunodeficiency Virus (HIV)
      • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
      • Positive SARS-CoV-2 antigen or PCR test within 30 days prior to Cycle 1 Day 1
      • Prior solid organ transplantation
      • Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
      • Clinically significant history of liver disease
      • Prior treatment with radiotherapy within 2 weeks prior to Cycle 1, Day 1 (C1D1)
      • Significant cardiovascular disease

      Exclusion Criteria Specific to Cohort A

      Participants in Cohort A who meet the following criteria will be excluded from study entry:

      • Prior anti-lymphoma treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to C1D1

      Exclusion Criterion Specific to Cohorts B and C

      Participants in Cohorts B and C who meet the following criterion will be excluded from study entry:

      • Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy

      Exclusion Criteria Specific to Cohort C

      Participants in Cohort C who meet the following criteria will be excluded from study entry:

      • Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now